相似文献
1
New Horizons in Immunology and Immunotherapy of Acute Leukemias and Related Disorders.
Cancers (Basel). 2023 Apr 23;15(9):2422. doi: 10.3390/cancers15092422.
2
Classification of acute leukemias.
Semin Diagn Pathol. 2003 Aug;20(3):142-53. doi: 10.1016/s0740-2570(03)00031-5.
3
Molecular events in follicular thyroid tumors.
Cancer Treat Res. 2004;122:85-105. doi: 10.1007/1-4020-8107-3_4.
4
Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?
Pharmacotherapy. 2017 Sep;37(9):1052-1072. doi: 10.1002/phar.1977. Epub 2017 Jul 31.
5
Immunotherapy in Acute Leukemias: Implications and Perspectives Using Wt1 Antigen.
Anticancer Res. 2016 Aug;36(8):3795-802.
6
Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.
Surg Today. 2018 Jan;48(1):1-8. doi: 10.1007/s00595-017-1497-7. Epub 2017 Mar 9.
7
Acute leukemias: a paradigm for the integration of new technologies in diagnosis and classification.
Mod Pathol. 1999 Feb;12(2):218-28.
8
Immunotherapy for myeloid leukemias: current status and future directions.
Leukemia. 2008 Sep;22(9):1658-64. doi: 10.1038/leu.2008.148. Epub 2008 Jun 19.
9
Molecular diagnosis in pediatric acute leukemias.
Clin Lab Med. 2000 Mar;20(1):139-82, x.
10
Impact of Genetics on Mature Lymphoid Leukemias and Lymphomas.
Cold Spring Harb Perspect Med. 2020 Nov 2;10(11):a035444. doi: 10.1101/cshperspect.a035444.
引用本文的文献
1
Acute Myeloid Leukemia: Updates on Diagnosis, Treatment and Management.
Cancers (Basel). 2025 Jul 18;17(14):2387. doi: 10.3390/cancers17142387.
2
Novel insights and therapeutic approaches in secondary AML.
Front Oncol. 2024 Jul 29;14:1400461. doi: 10.3389/fonc.2024.1400461. eCollection 2024.
本文引用的文献
1
WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1.
Cancers (Basel). 2023 Jan 6;15(2):393. doi: 10.3390/cancers15020393.
2
Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment.
Cancers (Basel). 2023 Jan 6;15(2):375. doi: 10.3390/cancers15020375.
3
Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer.
Cancers (Basel). 2022 Nov 18;14(22):5678. doi: 10.3390/cancers14225678.
4
A Novel Potential Role for Monocytes Revealed by Single Cell Analysis of Immunotherapy Induced Immune Related Adverse Events.
Cancers (Basel). 2022 Nov 2;14(21):5407. doi: 10.3390/cancers14215407.
5
Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand?
Cancers (Basel). 2022 Jun 17;14(12):2994. doi: 10.3390/cancers14122994.
6
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells.
Cancers (Basel). 2022 Jun 11;14(12):2886. doi: 10.3390/cancers14122886.
7
WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma.
J Immunother Cancer. 2022 Jun;10(6). doi: 10.1136/jitc-2021-004409.
8
First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience.
Cancer Immunol Immunother. 2022 Dec;71(12):2913-2928. doi: 10.1007/s00262-022-03202-8. Epub 2022 Apr 27.
9
Immunotherapy for Acute Myeloid Leukemia: Allogeneic hematopoietic cell transplantation is here to stay.
Leuk Res. 2022 Jan;112:106732. doi: 10.1016/j.leukres.2021.106732. Epub 2021 Oct 21.
10
Targeted Therapies and Druggable Genetic Anomalies in Acute Myeloid Leukemia: From Diagnostic Tools to Therapeutic Interventions.
Cancers (Basel). 2021 Sep 19;13(18):4698. doi: 10.3390/cancers13184698.
Zotero 插件